84 related articles for article (PubMed ID: 11910867)
1. [Better tumor eradication in transgenic altered T-lymphocytes. Role of the TGF-beta signal transduction cascade].
Hautarzt; 2001 Dec; 52(12):1135-6. PubMed ID: 11910867
[No Abstract] [Full Text] [Related]
2. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
Gorelik L; Flavell RA
Nat Med; 2001 Oct; 7(10):1118-22. PubMed ID: 11590434
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
4. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
5. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
[TBL] [Abstract][Full Text] [Related]
6. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
[TBL] [Abstract][Full Text] [Related]
7. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
Jia ZC; Zou LY; Ni B; Wan Y; Zhou W; Lv YB; Geng M; Wu YZ
Cancer Immunol Immunother; 2005 May; 54(5):446-52. PubMed ID: 15750831
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta regulates pathology but not tissue CD8+ T cell dysfunction during experimental Trypanosoma cruzi infection.
Martin DL; Postan M; Lucas P; Gress R; Tarleton RL
Eur J Immunol; 2007 Oct; 37(10):2764-71. PubMed ID: 17823982
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma.
Yang F; Strand DW; Rowley DR
Oncogene; 2008 Jan; 27(4):450-9. PubMed ID: 17637743
[TBL] [Abstract][Full Text] [Related]
10. Transforming growth factor-beta pathway serves as a primary tumor suppressor in CD8+ T cell tumorigenesis.
Lucas PJ; McNeil N; Hilgenfeld E; Choudhury B; Kim SJ; Eckhaus MA; Ried T; Gress RE
Cancer Res; 2004 Sep; 64(18):6524-9. PubMed ID: 15374963
[TBL] [Abstract][Full Text] [Related]
11. Complementary role of CD4+CD25+ regulatory T cells and TGF-beta in oral tolerance.
Chung Y; Lee SH; Kim DH; Kang CY
J Leukoc Biol; 2005 Jun; 77(6):906-13. PubMed ID: 15758078
[TBL] [Abstract][Full Text] [Related]
12. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
[TBL] [Abstract][Full Text] [Related]
13. Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II.
Zhao W; Kobayashi M; Ding W; Yuan L; Seth P; Cornain S; Wang J; Okada F; Hosokawa M
Cancer Immunol Immunother; 2002 Sep; 51(7):381-8. PubMed ID: 12192538
[TBL] [Abstract][Full Text] [Related]
14. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
Koehler H; Kofler D; Hombach A; Abken H
Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
[TBL] [Abstract][Full Text] [Related]
15. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
17. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
[TBL] [Abstract][Full Text] [Related]
18. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta signaling regulates CD8+ T cell responses to high- and low-affinity TCR interactions.
Mehal WZ; Sheikh SZ; Gorelik L; Flavell RA
Int Immunol; 2005 May; 17(5):531-8. PubMed ID: 15824070
[TBL] [Abstract][Full Text] [Related]
20. Glioma gene therapy with soluble transforming growth factor-beta receptors II and III.
Naumann U; Maass P; Gleske AK; Aulwurm S; Weller M; Eisele G
Int J Oncol; 2008 Oct; 33(4):759-65. PubMed ID: 18813789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]